|
|
Post by compound26 on Mar 2, 2017 11:55:31 GMT -5
|
|
|
|
Post by brotherm1 on Mar 2, 2017 12:28:34 GMT -5
Nice! Jackie's paying $30 compared to $100 with her prior needle injections. And some insurance coverage for the area is mentioned. Well done. Best news ad yet imo. Thx compound
|
|
|
|
Post by dreamboatcruise on Mar 2, 2017 18:52:09 GMT -5
Too bad they threw in that "can't be used when you have a cold" nonsense.
|
|
|
|
Post by compound26 on Mar 2, 2017 19:13:02 GMT -5
Too bad they threw in that "can't be used when you have a cold" nonsense. But overall still an excellent report. The user is very happy and enthusiastic. Showed the user dosing the Afrezza in a happy environment (dining in a restaurant). Showed a scene where the user is saying that "that's (Afrezza) all I needed" for controlling my diabetes. Also clearly stated in this case Afrezza actually saved money (a lot cheaper) compared with RAAs (30$ copay vs $100 copay)! So for this user, much happier life switching from RAAs to Afrezza. And the reporter also did some research on the cost of Afrezza by pooling information from the various insurers and shared such information to the public. That's also helpful. Anyway, this is a much improved report compared with the first few reports that we saw sponsored by Sanofi (see link below), where we just had someone (looks like a diabetes educator) just stated that there is an inhaled insulin available, but then just went through all the situations where Afrezza can not be prescribed. My overall impression is that this report (other than the mistake they made regarding taking Afrezza when you have a cold) is very pleasant to watch (and I do not mind watching it several times) and watching it leaves me (pretending that I knew nothing of Afrezza before watching this report) the impression that Afrezza is something really good. While the report below is not so pleasant to watch and I probably will not watch it more than one time and after watching it, I do not have much impression of what Afrezza is. |
|
|
|
Post by dreamboatcruise on Mar 2, 2017 20:30:52 GMT -5
compound26... Big difference between news coverage "report" and marketing/advertising material. Sanofi then and Mannkind now aren't allowed by FDA to do a "report" like this having an individual talk about anecdotal experience. News outlets have no such constraint. As far as I know they wouldn't even have to provide the contraindications, but often choose to do so in the service of good reporting.
|
|
|
|
Post by nylefty on Mar 2, 2017 21:52:29 GMT -5
compound26 ... Big difference between news coverage "report" and marketing/advertising material. Sanofi then and Mannkind now aren't allowed by FDA to do a "report" like this having an individual talk about anecdotal experience. News outlets have no such constraint. As far as I know they wouldn't even have to provide the contraindications, but often choose to do so in the service of good reporting. Well said. As somebody who spent many years in radio and TV news I get frustrated by all the MNKD investors who call for commercials with anecdotal stories. How many times do they have to be told that the FDA would never approve such ads? But news outlets can include all the anecdotes they want and yes they don't have to include contra-indications. |
|
|
|
Post by factspls88 on Mar 3, 2017 9:11:04 GMT -5
This is excellent. They make all the relevant claims except for fewer hypos. I'll be glad when the FDA gives a go to the hypo claim. One of the best tv spots I've seen. Thanks for posting!
|
|
You can access it via one of the following links:
You can access it via one of the following links:
